GHRP-6, or Growth Hormone Releasing Peptide-6, is a peptide studied mainly for its ability to stimulate growth hormone release and related pituitary-adrenal hormones. Human research exists, including randomized trials, but most evidence is endocrine-testing focused—not proof of muscle gain, fat loss, or longevity benefits. Chia does not offer GHRP-6.
Wondering if sermorelin is right for you? Take the 3-min clinical quiz.
See if you qualify →What it is
GHRP-6 stands for Growth Hormone Releasing Peptide-6. It is a synthetic growth hormone-releasing peptide, a class of compounds studied for signals that can increase growth hormone, or GH, release from the pituitary gland 1.
In the supplied human literature, GHRP-6 appears mainly in endocrine testing and physiology studies, including work in adults with growth hormone deficiency and studies of thyroid, adrenal, cortisol, exercise, and sleep-related hormone responses 1 3 4 5 6.
That matters because endocrine-response studies answer a narrow question: “Does this compound move a hormone signal under study conditions?” They do not answer broader consumer questions like “Will it build muscle?” or “Will it support longevity?” The supplied records do not establish those outcomes for GHRP-6.
| Term | Plain-language meaning | Why it matters |
|---|---|---|
| GHRP-6 | Growth Hormone Releasing Peptide-6 | The main compound on this page; studied as a GH-releasing stimulus 1. |
| GH | Growth hormone | A pituitary hormone measured in several GHRP-6 studies 2 6. |
| GHRH | Growth hormone-releasing hormone | A hypothalamic signal often compared with GHRP-6 in endocrine testing 1 4. |
| ACTH and cortisol | Pituitary-adrenal hormones | Measured in human GHRP-6 studies involving Addison’s disease, thyrotoxicosis, sleep, and related endocrine contexts 3 5 6. |
| Hexarelin | A synthetic growth hormone-releasing peptide described as a GHRP-6 analog in the supplied literature | Studied separately; it should not be treated as identical to GHRP-6 9 10. |
Mechanism of action
GHRP-6 is studied as a growth hormone secretagogue, meaning a compound that can stimulate GH release. In human endocrine research, its GH response has been studied alongside GHRH, the hypothalamus-to-pituitary signal that normally helps drive GH release 1 2.
One key concept is that GHRP-6 does not act in isolation. A randomized human study reported that maximal GH stimulation from GHRP-6 requires endogenous hypothalamic GHRH activity, which means the body’s own GHRH signal can shape the response 2.
GHRP-6 is also discussed in the same research family as ghrelin signaling, because supplied human studies measured ghrelin and GHRP-6-induced ACTH and cortisol release in thyrotoxicosis 5. This supports a careful view: the demonstrated human evidence is hormone-response evidence, not proof of body-composition or longevity outcomes.
Growth hormone release, GHRH, and ghrelin-signaling concepts
The pituitary gland releases GH in pulses. GHRH from the hypothalamus helps drive that process, and GHRP-6 has been studied as another stimulus that can affect GH release in people under test conditions 1 2.
Human studies also show that clinical context matters. GHRP-6 responses were studied in hypothyroidism, hypercortisolism, exercise-related GH release, and sleep-related hormone secretion, which means thyroid state, cortisol state, physical stress, and route of administration may affect the measured hormone response 4 6 7 8.
ACTH, cortisol, prolactin, and appetite-related signals
The supplied literature does not only measure GH. Human trials also measured ACTH and cortisol after GHRP-6 exposure in Addison’s disease, thyrotoxicosis, and nocturnal hormone studies 3 5 6.
Prolactin is best supported here by hexarelin research, not direct GHRP-6 research. Hexarelin was described as a synthetic growth hormone-releasing peptide or GHRP-6 analog in supplied papers, and it was studied for prolactin and GH secretion; that does not make hexarelin and GHRP-6 interchangeable 9 10.
People often ask whether GHRP-6 affects hunger. The supplied records support discussion of ghrelin-related endocrine signaling, but they do not provide a consumer-outcome trial proving a predictable appetite effect for all users 5.
Evidence
GHRP-6 receives evidence grade A in the supplied evidence set because multiple human randomized controlled trials are indexed in PubMed. That grade is about the amount and design of evidence, not a claim that GHRP-6 is effective or safe for consumer goals 2 4 7 8 10.
The strongest human evidence in the supplied set is not an outcomes program for muscle, fat loss, recovery, or lifespan. It is mostly endocrine physiology: GH responses, diagnostic testing, ACTH and cortisol responses, sleep EEG measurements, and responses in endocrine conditions such as hypothyroidism, hypercortisolism, Addison’s disease, and thyrotoxicosis 1 3 4 5 6.
Animal evidence also exists. One supplied randomized controlled trial studied growth hormone-releasing peptides in healthy dogs and dogs with pituitary-dependent hyperadrenocorticism; because this is animal research, it should not be used as proof of human benefit or safety 11.
| Evidence question | What the supplied literature supports | What it does not prove |
|---|---|---|
| Can GHRP-6 stimulate GH signals in humans? | Human trials studied GH responses to GHRP-6 in diagnostic and endocrine contexts 1 2. | It does not prove better strength, muscle gain, fat loss, or longevity. |
| Does clinical context matter? | Studies examined hypothyroidism, hypercortisolism, glucocorticoid excess, Addison’s disease, and thyrotoxicosis 3 4 5 7 10. | It does not create a simple one-size-fits-all interpretation. |
| Is GHRP-6 the same as hGH? | No. The studies describe GHRP-6 as a GH-releasing stimulus, while hGH is growth hormone itself 1 2. | It does not mean risks, effects, or monitoring are identical. |
| Is hexarelin the same compound? | No. Hexarelin is described as a GHRP-6 analog or synthetic growth hormone-releasing peptide in supplied studies 9 10. | Findings from hexarelin should not be copied onto GHRP-6 without caution. |
What human trials can and cannot prove
A human randomized trial can show a measured effect under controlled conditions, such as a hormone response. It does not automatically show that a compound improves how someone feels, performs, ages, or recovers 2 6 8.
That is the main limitation for GHRP-6. The supplied studies support a real endocrine-research history, but they do not establish consumer outcomes like muscle growth, fat loss, anti-aging, or longer life.
Why endocrine-response studies are not the same as outcomes studies
Hormones are signals, not final outcomes. For example, a study can measure GH, ACTH, cortisol, or sleep EEG after GHRP-6 exposure, but that still does not tell us whether a person gains muscle, loses fat, sleeps better long term, or has fewer injuries 6.
For readers comparing GHRP-6 with other GH-axis peptides, our deeper guides on GHRP-6, sermorelin, ipamorelin, and CJC-1295 explain how the evidence differs by compound.
What studies exist
| Year | Design | Study | Journal | Record |
|---|---|---|---|---|
| 2002 | Randomised controlled trial | Effects of growth hormone-releasing peptides in healthy dogs and in dogs with pituitary-dependent hyperadrenocorticism | Molecular and cellular endocrinology | PMID 12431802 |
| 2000 | Clinical trial | GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults | Lancet (London, England) | PMID 11030292 |
| 1995 | Randomised controlled trial | Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man | Neuroendocrinology | PMID 7617137 |
| 1997 | Randomised controlled trial | Growth hormone responses to GH-releasing peptide (GHRP-6) in hypothyroidism | Clinical endocrinology | PMID 9156038 |
| 2003 | Clinical trial | GH-releasing peptide (GHRP-6)-induced ACTH release in patients with addison's disease: effect of glucocorticoid withdrawal | Journal of endocrinological investigation | PMID 12739742 |
| 1997 | Randomised controlled trial | Influence of endogenous cholinergic tone and growth hormone-releasing peptide-6 on exercise induced growth hormone release | Clinical endocrinology | PMID 9135702 |
| 2009 | Clinical trial | Ghrelin and GHRP-6-induced ACTH and cortisol release in thyrotoxicosis | Pituitary | PMID 19396632 |
| 1997 | Randomised controlled trial | Different effects of growth hormone releasing peptide (GHRP-6) and GH-releasing hormone on GH release in endogenous and exogenous hypercortisolism | Clinical endocrinology | PMID 9274702 |
| 1999 | Clinical trial | Effects of growth hormone-releasing peptide-6 on the nocturnal secretion of GH, ACTH and cortisol and on the sleep EEG in man: role of routes of administration | Journal of neuroendocrinology | PMID 10336729 |
| 1995 | Clinical trial | Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature | European journal of endocrinology | PMID 7581965 |
| 1995 | Randomised controlled trial | Comparison of the effects of growth hormone-releasing hormone and hexarelin, a novel growth hormone-releasing peptide-6 analog, on growth hormone secretion in humans with or withou | The Journal of endocrinology | PMID 7561633 |
| 1993 | Clinical trial | Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6 | The Journal of clinical endocrinology and metabolism | PMID 8077339 |
This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-09.
Reported dosing ranges
GHRP-6 dosing decisions require a licensed clinician’s evaluation. The supplied PubMed record strings confirm that human and animal studies were published, but they do not provide extractable dose ranges in the source text available here; we will not invent dosing numbers or turn study designs into personal instructions.
| Source | Population or model | What was studied | Dose range available from supplied source text? |
|---|---|---|---|
| Popovic et al., 2000 1 | Adults with growth hormone deficiency | GHRH and GHRP-6 for diagnostic testing | No dose range provided in the supplied citation text |
| Pandya et al., 1998 2 | Human randomized study | Need for endogenous hypothalamic GHRH for maximal GH stimulation | No dose range provided in the supplied citation text |
| Frieboes et al., 1999 6 | Human clinical trial | Nocturnal GH, ACTH, cortisol, sleep EEG, and route of administration | No dose range provided in the supplied citation text |
| Pimentel-Filho et al., 1997 4 | People with hypothyroidism | GH responses to GHRP-6 | No dose range provided in the supplied citation text |
| Bhatti et al., 2002 11 | Animal study in dogs | Growth hormone-releasing peptides in healthy dogs and dogs with pituitary-dependent hyperadrenocorticism | No human dose range; animal findings cannot be converted into human dosing |
Route also matters. A human clinical trial specifically examined the role of routes of administration on nocturnal GH, ACTH, cortisol, and sleep EEG after GHRP-6 exposure, which is one reason route-specific claims should not be guessed from a generic dosing chart 6.
Legal status
Our regulatory log holds no confirmed federal action for GHRP-6. That means we have not found one with a primary source — not that none exists.
This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-09. See the full legal-status tracker for every compound we follow.
Safety
GHRP-6 safety cannot be judged only by whether it moves GH. The supplied human studies show that GHRP-6-related testing can involve GH, ACTH, cortisol, thyroid status, adrenal disease, hypercortisolism, exercise physiology, and sleep signals, so endocrine context is central to risk review 3 4 5 6 7 8.
Possible safety concerns include unwanted hormone shifts, changes in cortisol-related signaling, and uncertain effects in people with pituitary, adrenal, thyroid, metabolic, pregnancy-related, or cancer-history concerns. The supplied studies support clinician caution because they specifically examine endocrine disease states and hormone responses, not broad long-term safety in healthy consumers 3 4 5 7.
Research-chemical sourcing adds a separate safety problem. Material sold outside clinical care may not be made for people, and the main practical risks are identity, purity, sterility, storage, and whether the vial or capsule contains what the label says.
| Safety question | Why it matters | Evidence context |
|---|---|---|
| Pituitary and GH-axis effects | GHRP-6 is studied because it can stimulate GH signals. | Human diagnostic and endocrine-response trials measured GH responses 1 2. |
| Adrenal signals | ACTH and cortisol changes may matter for people with adrenal disease or steroid exposure. | Human studies examined ACTH and cortisol responses in Addison’s disease, thyrotoxicosis, sleep studies, and hypercortisolism 3 5 6 7. |
| Thyroid disease | Thyroid status can change endocrine interpretation. | A randomized human study evaluated GH responses to GHRP-6 in hypothyroidism, and another studied ghrelin and GHRP-6-induced ACTH and cortisol release in thyrotoxicosis 4 5. |
| Sleep-related hormone signals | Short-term sleep EEG and nocturnal hormones are not the same as long-term sleep benefit. | A human study measured nocturnal GH, ACTH, cortisol, and sleep EEG after GHRP-6 exposure 6. |
| Analog confusion | Hexarelin data should not be treated as direct GHRP-6 data. | Hexarelin was studied separately and described as a GHRP-6 analog or synthetic growth hormone-releasing peptide 9 10. |
| Animal-to-human overreach | Animal findings cannot prove human outcomes. | A supplied randomized controlled trial involved dogs, so it must be read as animal evidence 11. |
Hormone-related safety questions
The main safety question is not just “Does GH rise?” It is “What else changes, in whom, and under what conditions?” Human studies measured ACTH, cortisol, thyroid-related contexts, adrenal disease contexts, and sleep EEG, which is why clinician review matters 3 4 5 6.
Why appetite stimulation matters
Because GHRP-6 is linked in the supplied literature to ghrelin-related endocrine testing, appetite questions are reasonable. But the supplied records do not establish a clear, predictable appetite outcome for every person using GHRP-6 5.
Why people with endocrine conditions need clinician review
People with thyroid disease, adrenal disease, pituitary disorders, glucocorticoid exposure, metabolic disease, pregnancy-related concerns, or a cancer history should not self-experiment with GH-axis compounds. The supplied studies show that these endocrine contexts can change how hormone-response data are interpreted 3 4 5 7 10.
Interactions
GHRP-6 does not have broad drug-interaction trials in the supplied evidence set. What the records do show is that thyroid disease, adrenal disease, glucocorticoid excess, hypercortisolism, and exercise physiology were important enough to study as separate contexts 3 4 5 7 8 10.
Glucocorticoids and cortisol biology deserve special caution. Human randomized studies examined different GH responses to GHRP-6, GHRH, or hexarelin in endogenous and exogenous hypercortisolism or glucocorticoid excess 7 10.
Thyroid status also matters. A randomized human study evaluated GH responses to GHRP-6 in hypothyroidism, and a separate clinical trial examined ghrelin and GHRP-6-induced ACTH and cortisol release in thyrotoxicosis 4 5.
| Medication or condition area | Why to discuss it with a clinician | Evidence context |
|---|---|---|
| Glucocorticoids or cortisol disorders | Cortisol state may change GH-response interpretation. | Human studies examined hypercortisolism and glucocorticoid excess 7 10. |
| Thyroid disease | Thyroid state may affect endocrine response. | Human studies examined hypothyroidism and thyrotoxicosis contexts 4 5. |
| Adrenal disease | ACTH and cortisol signals are part of the adrenal axis. | A human clinical trial studied GHRP-6-induced ACTH release in Addison’s disease 3. |
| Pituitary disorders or GH deficiency | The compound acts through GH-axis signaling. | GHRH and GHRP-6 were studied for diagnostic testing in GH-deficient adults 1. |
| hGH, GHRH analogs, and GH secretagogues | These are related concepts but not interchangeable treatments. | Human studies compared GHRP-6 with GHRH and studied hexarelin separately as an analog 1 7 10. |
Why hGH, GHRH analogs, and GH secretagogues are not interchangeable
hGH is growth hormone itself. GHRH is a hypothalamic hormone signal. GHRP-6 is a peptide studied as a GH-releasing stimulus, and hexarelin is a separate analog studied in its own papers 1 2 9 10.
That distinction matters for safety. Different GH-axis compounds can have different hormone patterns, monitoring needs, and evidence limits, so findings from one should not be copied onto another.
How to obtain it legally
GHRP-6 is education-only at Chia. We do not offer GHRP-6, and we do not want a reader to confuse an evidence review with an offer to prescribe, compound, sell, or ship it.
For any hormone-active peptide question, the safer process starts with a licensed clinician evaluation. That review should cover goals, medical history, medications, labs when appropriate, endocrine risks, contraindications, sourcing, and monitoring; a prescription requires medical evaluation and is not guaranteed.
A licensed pharmacy is different from a research-chemical vendor. In clinical care, the prescriber and pharmacy are accountable for patient use; “research use only” material is not made for people, and may raise identity, sterility, impurity, storage, and labeling concerns.
Chia does offer other clinician-reviewed peptide and longevity options that are part of our current catalog, including sermorelin in injection, nasal spray, and tablet forms; NAD+ as injection or nasal spray; glutathione as injection or nasal spray; and GHK-Cu cream. Chia medications are compounded in the US by state-licensed 503A pharmacies and shipped to the patient’s door; compounded medications are not FDA-approved.
If your real question is about GH-axis peptides rather than GHRP-6 specifically, our guides to buying sermorelin online safely, sermorelin evidence, and peptides for muscle growth may be more practical next reads.
FAQ
GHRP-6 has been studied mainly for hormone-response and endocrine-testing questions, especially growth hormone release. The supplied evidence does not prove that it builds muscle, causes fat loss, improves recovery, or extends lifespan.
This page cannot give personal timing or dosing advice. Timing depends on the study design or clinical context, and any real-world decision about a hormone-active compound should be made with a licensed clinician.
No. hGH is growth hormone itself. GHRP-6 is a peptide studied as a signal that can stimulate growth hormone release. Those are different concepts and should not be treated as interchangeable.
GHRP-6 is related in the research literature to ghrelin-signaling concepts, so appetite questions are common. But the supplied studies do not prove a predictable hunger effect for every person.
No. Sermorelin, ipamorelin, and GHRP-6 are all discussed in the broader GH-axis peptide space, but they are different compounds with different evidence bases. Chia offers sermorelin, but does not offer GHRP-6.
The assigned evidence grade is A because the supplied PubMed set includes two or more human randomized controlled trials. That grade describes the quantity and design of published evidence, not whether GHRP-6 works or is safe for a specific goal.
The supplied evidence should not be read that way. Most studies measured endocrine responses such as GH, ACTH, cortisol, or related testing signals, not body-composition outcomes.
Research-use material is not made for patient care. The main risks are identity, purity, sterility, impurities, storage, and whether the product contains what the label claims.
References
- 1.Popovic V, Leal A, Micic D, et al. GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults. Lancet (London, England). 2000.
- 2.Pandya N, DeMott-Friberg R, Bowers CY, et al. Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. The Journal of clinical endocrinology and metabolism. 1998.
- 3.Martins MR, Pinto AC, Brunner E, et al. GH-releasing peptide (GHRP-6)-induced ACTH release in patients with addison's disease: effect of glucocorticoid withdrawal. Journal of endocrinological investigation. 2003.
- 4.Pimentel-Filho FR, Ramos-Dias JC, Ninno FB, et al. Growth hormone responses to GH-releasing peptide (GHRP-6) in hypothyroidism. Clinical endocrinology. 1997.
- 5.Nascif SO, Molica P, Correa-Silva SR, et al. Ghrelin and GHRP-6-induced ACTH and cortisol release in thyrotoxicosis. Pituitary. 2009.
- 6.Frieboes RM, Murck H, Antonijevic IA, et al. Effects of growth hormone-releasing peptide-6 on the nocturnal secretion of GH, ACTH and cortisol and on the sleep EEG in man: role of routes of administration. Journal of neuroendocrinology. 1999.
- 7.Borges MH, DiNinno FB, Lengyel AM. Different effects of growth hormone releasing peptide (GHRP-6) and GH-releasing hormone on GH release in endogenous and exogenous hypercortisolism. Clinical endocrinology. 1997.
- 8.Nooitgedagt A, Koppeschaar HP, de Vries WR, et al. Influence of endogenous cholinergic tone and growth hormone-releasing peptide-6 on exercise induced growth hormone release. Clinical endocrinology. 1997.
- 9.Ciccarelli E, Grottoli S, Razzore P, et al. Hexarelin, a synthetic growth hormone releasing peptide, stimulates prolactin secretion in acromegalic but not in hyperprolactinaemic patients. Clinical endocrinology. 1996.
- 10.Giustina A, Bussi AR, Deghenghi R, et al. Comparison of the effects of growth hormone-releasing hormone and hexarelin, a novel growth hormone-releasing peptide-6 analog, on growth hormone secretion in humans with or without glucocorticoid excess. The Journal of endocrinology. 1995.
- 11.Bhatti SF, De Vliegher SP, Van Ham L, et al. Effects of growth hormone-releasing peptides in healthy dogs and in dogs with pituitary-dependent hyperadrenocorticism. Molecular and cellular endocrinology. 2002.
- 12.Hernández-Bernal F, Subirós-Martínez N, Gutiérrez-Ronquillo JH, et al. Phase III Open-Label, Randomized Clinical Trial of Epidermal Growth Factor and Growth Hormone Releasing Hexapeptide in Acute Ischemic Stroke. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if sermorelin is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
